Drug Trial Radar · NCT04182880
Evaluate the Safety and Pharmacokinetic Profile of CPL-01 in the Management of Acute Postoperative Pain
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Jan 6, 2020
Primary completion
Feb 28, 2020
Study completion Feb 28, 2020
Sponsor
- Lead sponsor
- Cali Pharmaceuticals LLCIndustry
- Sponsor type
- Industry
- First posted
- Dec 2, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Evaluate the Safety and Pharmacokinetic Profile of CPL-01 in patients after mini-abdominoplasty
Conditions
- Abdominoplasty
Interventions
CPL-01Drug
CPL-01 will be administered
PlaceboDrug
Placebo will be administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean (Peak) Plasma Concentration (Cmax)Time frame: Baseline through 120 hours after start of study drug administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chesapeake Research Group
Pasadena, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.